Home Gilead paying up to $1.2B for Nimbus unit, drug candidate
 

Keywords :   


Gilead paying up to $1.2B for Nimbus unit, drug candidate

2016-04-04 22:15:41| Biotech - Topix.net

Biologic drugmaker Gilead Sciences Inc. said Monday that it will buy a subsidiary of Nimbus Therapeutics LLC and its experimental pill for an increasingly common metabolic disorder that causes life-threatening fat buildup in the liver. Gilead, based in Foster City, California, will pay $400 million for Nimbus Apollo Inc. Parent company Nimbus Therapeutics, based in Cambridge, Massachusetts, could receive another $800 million if Nimbus Apollo's drug development program meets certain milestones in testing results and medicine approval and sales.

Tags: unit drug candidate paying

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
16.11LL
16.11 1.2.3.4.5.6.
16.11KTF 21SVTW
16.11 a
16.11 Lord Finesse From The Crates To The File
16.11AB6IX
16.11TOMIX JR EF63()
16.11
More »